Drug Profile
Research programme: angiogenesis inhibitors - Bausch & Lomb/Teva Pharmaceutical Industries
Alternative Names: Eye disorder therapeutics - Bausch & Lomb/Teva Pharmaceutical IndustriesLatest Information Update: 30 Oct 2007
Price :
$50
*
At a glance
- Originator Cephalon
- Class Small molecules
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Age-related macular degeneration; Diabetic macular oedema
Most Recent Events
- 27 Oct 2007 Bausch and Lomb has been acquired by Warburg Pincus
- 13 Dec 2005 Preclinical trials in Age-related macular degeneration in USA (unspecified route)
- 13 Dec 2005 Preclinical trials in Diabetic macular oedema in USA (unspecified route)